Trial Profile
Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Emixustat (Primary)
- Indications Dry age-related macular degeneration; Dry macular degeneration
- Focus Pharmacokinetics
- Sponsors Acucela; Kubota Vision
- 20 Feb 2020 According to an Acucela media release, the company has changed its name to Kubota Vision, effective from 1 Apr 2020.
- 15 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 17 Jul 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.